- |||||||||| ST400 / Sangamo Therap, Sanofi
Journal: Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Causing Nosocomial Meningitis in the Neurological Intensive Care Unit. (Pubmed Central) - Aug 26, 2023 Virulence genes of nine groups (Adherence, Biofilm formation, Enzymes, Immune evasion, Iron uptake, Regulation, Serum resistance, Stress adaptation, and Antiphagocytosis) were detected. The study highlights the heterogeneity in genetic clones, antimicrobial resistance, and virulence genes variability among the agents of A. baumannii meningitis, with the prevalence of the dominant international clone IC2.
- |||||||||| ST400 / Sangamo Therap, Sanofi
Trial completion: A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) (clinicaltrials.gov) - Jan 30, 2023 P1/2, N=5, Completed, The study highlights the heterogeneity in genetic clones, antimicrobial resistance, and virulence genes variability among the agents of A. baumannii meningitis, with the prevalence of the dominant international clone IC2. Active, not recruiting --> Completed
- |||||||||| ST400 / Sangamo Therap, Sanofi, BIVV003 / Sangamo Therap, Sanofi
Enrollment status, Gene therapy: Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400. (clinicaltrials.gov) - Dec 19, 2022 P=N/A, N=12, Enrolling by invitation, Low resistance to ceftriaxone, a worrying resistance to azithromycin and a wide variety of circulating sequence types have been detected, some of which show correlation with certain resistance profiles. Recruiting --> Enrolling by invitation
- |||||||||| sirolimus / Generic mfg.
Journal: β-Thalassemia: evolving treatment options beyond transfusion and iron chelation. (Pubmed Central) - Feb 16, 2022 In addition, 2 gene editing techniques (CRISPR-Cas9 and zinc-finger nucleases) are under investigation as a means to silence BCL11A to induce HbF with agents designated CTX001 and ST-400, respectively. Results from the many clinical trials for these agents will yield results in the next few years, which may end the era of relying on transfusion alone as the mainstay of thalassemia therapy.
- |||||||||| ST400 / Sangamo Therap, Sanofi, BIVV003 / Sangamo Therap, Sanofi
Trial completion date, Trial primary completion date, Gene therapy: Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400. (clinicaltrials.gov) - Feb 1, 2022 P=N/A, N=13, Recruiting, Results from the many clinical trials for these agents will yield results in the next few years, which may end the era of relying on transfusion alone as the mainstay of thalassemia therapy. Trial completion date: Mar 2043 --> Aug 2037 | Trial primary completion date: Mar 2043 --> Aug 2037
- |||||||||| Branigen (acetyl-L-carnitine) - Mitsubishi Tanabe, Dong / A, Leadiant Biosci, ST400 / Sangamo Therap, Sanofi
Clinical, Journal: Effect of Photobiomodulation on Critical Swimming Velocity: A Randomized, Crossover, Double-Blind, and Placebo-Controlled Study. (Pubmed Central) - Jul 28, 2021 After 1 to 2 years, the average HbF levels had declined by 64% from peak to last visit, which necessitated resumption of PRBC transfusions at the same rate as prior to the ST-400 therapy. A PBM application prior to front crawl swimming test did not significantly modify the CV, ST, physiological factors of metabolic fatigue, perceptual, and front crawl stroke efficiency parameters in competition swimmers covering distances of 100, 200, and 400 m.
- |||||||||| ampicillin / Generic mfg.
[VIRTUAL] Campylobacter Genotypes Present At Austrian Broiler Farm Level Indicate Global Character (Poster Hall) - May 31, 2021 - Abstract #WMF2021WMF_5044; The following C. jejuni and C. coli genotypes were detectable in caecal samples at several sampling times: ST-267, ST-354, ST-400, ST-2066, ST-446 and ST-828...Antimicrobial resistance genes were detected in the isolates to ciprofloxacin, ampicillin and tetracycline...Since a co-selection of antibiotics and biocides is reported for particularly environmentally adapted genotypes, the isolates should be tested subsequently to gain insight into the potential adaptability of individual genotypes. The study will give an insight into the genetic diversity of thermophilic Campylobacter species in different Austria districts in order to help the poultry industry to track down the pathways of contamination, so that control measures can be implemented.
- |||||||||| vancomycin / Generic mfg., ST400 / Sangamo Therapeutics, Sanofi, BIVV003 / Sangamo Therapeutics, Sanofi
Clinical, Journal: Distribution of the optrA gene in Enterococcus isolates at a tertiary care hospital in China. (Pubmed Central) - Jun 19, 2020 Trial primary completion date: Mar 2021 --> Nov 2022 The emergence of linezolid-nonsusceptible enterococcus isolates with optrA-mediated resistance mechanisms and ST16 E. faecalis clonal dissemination in our hospital may pose a potential challenge to public health.
- |||||||||| Mozobil (plerixafor) / Sanofi, ST400 / Sangamo Therapeutics, Sanofi, BIVV003 / Sangamo Therapeutics, Sanofi
Zinc Finger Nuclease-Mediated Disruption of the BCL11A Erythroid Enhancer Results in Enriched Biallelic Editing, Increased Fetal Hemoglobin, and Reduced Sickling in Erythroid Cells Derived from Sickle Cell Disease Patients (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_1775; P1/2 Both related drug candidates, ST-400 and BIVV003, are currently in phase 1/2a clinical trials for transfusion-dependent BT (NCT03432364) and SCD (NCT03653247), respectively...Experiments in HSPCs from additional SCD donors are ongoing . Overall, our data have shown that ZFN-mediated disruption of BCL11A ESE results in enriched biallelic editing with on-target small indels, reactivates HbF and reduces sickling, supporting the potential efficacy and specificity of BIVV003 as a novel cell therapy for SCD.
- |||||||||| ST400 / Sangamo Therap, Sanofi
Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) (clinicaltrials.gov) - Feb 4, 2019 P1/2, N=6, Recruiting, Overall, our data have shown that ZFN-mediated disruption of BCL11A ESE results in enriched biallelic editing with on-target small indels, reactivates HbF and reduces sickling, supporting the potential efficacy and specificity of BIVV003 as a novel cell therapy for SCD. Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: May 2020 --> Dec 2020
|